Scientists have developed a pill which uses the stomach as a drug reservoir and delivers medicines slowly over time to patients with Parkinson's disease.
Metformin could be particularly beneficial for people with type 2 diabetes who are older or looking to become pregnant, as discovered by two separate studies.
The TGA has registered Novartis's LUXTURNA, the first gene therapy in Australia, for the treatment of patients with inherited retinal dystrophy.
The Australian Government has joined the COVAX facility, enabling the purchase of COVID-19 vaccine doses as they become available.
Launching a dual-pronged attack on tumours using a combination of two precision medicines could treat patients with multiple common cancers.
The system's automation capabilities include automated filter switching, liquid management and cell bleed, reducing risk for human error and increasing process robustness.
The bionic vision system makes it possible to treat many conditions that currently have treatment limitations, thanks to the use of electronic implants that sit on the surface of the brain.
Studies of critically ill patients with COVID-19 show that fewer patients died and less ICU support was required when patients received corticosteroids.
A phase 3 clinical trial has shown that a new drug boosts bone growth in children born with achondroplasia — the most common type of dwarfism.
Biotech company CSL has signed two separate heads of agreement (HoA) for COVID-19 vaccines should clinical trials prove successful.
Venom from honeybees has been found to induce cancer cell death in hard-to-treat triple-negative breast cancer, with minimal effect on healthy cells.
The NanoAssemblr platform from Precision Nanosystems enables the rapid, reproducible and scalable manufacture of next-generation nanoparticle formulations such as lipid nanoparticles and liposomes to encapsulate a payload such as a SAM.
The company has been launched in Queensland to help accelerate the development and commercialisation of Australian-born medical devices for the global market.
The formation of 'micropores' underneath the skin allows drugs applied on the surface to diffuse through it more easily.
The drugs work through a mechanism that is distinct from currently prescribed medicines for asthma and chronic obstructive pulmonary disease.